Ocean Biomedical (OCEA) is trading at $0.0001 on NASDAQ with a market capitalization of just $59,316 — one of the most distressed valuations observable in public biotech markets. Daily volume sits at 7,780 shares, and the stock recorded zero price movement in the last session. With no active job postings and no measurable web traffic trend, operational activity appears effectively dormant. The company is a clinical-stage biopharmaceutical firm developing antibody and small molecule therapies across oncology, fibrosis, and infectious disease, but its financial position reflects extreme deterioration.
TrendEdge's AI model assigns OCEA a score of 2 out of 10, placing it in the lowest tier of investment signals on the platform. The score reflects a convergence of deeply negative indicators: a sub-penny price at $0.0001, a market cap of under $60,000, zero Reddit mentions in the past 24 hours, and no identifiable operational growth signals such as hiring or web traffic. Volume is running at approximately 1.1 times its average, which may indicate residual speculative activity rather than informed accumulation. No positive momentum drivers are currently present in the model.
The most significant near-term event on the calendar is an earnings report expected in June 2026. While this could theoretically serve as a catalyst, the current data profile — zero job postings, no web traffic signal, and a micro-cap valuation — suggests structural rather than cyclical distress. Investors should monitor whether the company files updated clinical data on its Chi3l1 antibody or Chit1 small molecule programs. Liquidity risk is flagged as low by volume metrics alone, but the near-zero price creates practical trading barriers.
